BR112014013082A2 - método para detectar adutos nucleossomos - Google Patents

método para detectar adutos nucleossomos

Info

Publication number
BR112014013082A2
BR112014013082A2 BR112014013082A BR112014013082A BR112014013082A2 BR 112014013082 A2 BR112014013082 A2 BR 112014013082A2 BR 112014013082 A BR112014013082 A BR 112014013082A BR 112014013082 A BR112014013082 A BR 112014013082A BR 112014013082 A2 BR112014013082 A2 BR 112014013082A2
Authority
BR
Brazil
Prior art keywords
detecting
adducts
nucleosome
nucleosome adducts
detecting nucleosome
Prior art date
Application number
BR112014013082A
Other languages
English (en)
Other versions
BR112014013082B1 (pt
Inventor
Vincent Micallef Jacob
Herzog Marielle
Edward Eccleston Mark
Original Assignee
Singapore Volition Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201121040A external-priority patent/GB201121040D0/en
Priority claimed from GBGB1121230.5A external-priority patent/GB201121230D0/en
Application filed by Singapore Volition Pte Ltd filed Critical Singapore Volition Pte Ltd
Publication of BR112014013082A2 publication Critical patent/BR112014013082A2/pt
Publication of BR112014013082B1 publication Critical patent/BR112014013082B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Abstract

resumo "método para detectar adutos nucleossomos" a invenção relaciona-se a um método para detectar e medir a presença de adutos nucleossomo-proteína e o uso de tais medidas para a detecção e diagnóstico de doença. a invenção também se relaciona a um método de identificar biomarcadores de aduto de nucleossomo para a detecção e diagnóstico da doença e para biomarcadores identificados pelo referido método.
BR112014013082-5A 2011-12-07 2012-12-07 uso de um aduto nucleossomo-proteína e métodos para detectar a presença de um aduto nucleossomo-proteína BR112014013082B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161568090P 2011-12-07 2011-12-07
GB201121040A GB201121040D0 (en) 2011-12-07 2011-12-07 Method for detecting nucleosome adducts
GB1121040.8 2011-12-07
US61/568,090 2011-12-07
GB1121230.5 2011-12-12
GBGB1121230.5A GB201121230D0 (en) 2011-12-12 2011-12-12 Methods of detecting nucleosome adducts
PCT/GB2012/053057 WO2013084002A2 (en) 2011-12-07 2012-12-07 Method for detecting nucleosome adducts

Publications (2)

Publication Number Publication Date
BR112014013082A2 true BR112014013082A2 (pt) 2017-06-13
BR112014013082B1 BR112014013082B1 (pt) 2021-02-02

Family

ID=48575008

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013082-5A BR112014013082B1 (pt) 2011-12-07 2012-12-07 uso de um aduto nucleossomo-proteína e métodos para detectar a presença de um aduto nucleossomo-proteína

Country Status (20)

Country Link
US (3) US9187780B2 (pt)
EP (3) EP2788767B1 (pt)
JP (1) JP6263474B2 (pt)
KR (1) KR102039756B1 (pt)
CN (1) CN104067125B (pt)
AU (1) AU2012349855B2 (pt)
BR (1) BR112014013082B1 (pt)
CA (1) CA2855375C (pt)
DK (1) DK2788767T3 (pt)
ES (1) ES2649404T3 (pt)
HK (2) HK1202926A1 (pt)
HR (1) HRP20171680T1 (pt)
HU (1) HUE035855T2 (pt)
MX (1) MX356986B (pt)
PL (1) PL2788767T3 (pt)
PT (1) PT2788767T (pt)
RU (1) RU2634266C2 (pt)
SG (2) SG10201604081YA (pt)
WO (1) WO2013084002A2 (pt)
ZA (1) ZA201403260B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115095D0 (en) * 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
WO2013084002A2 (en) 2011-12-07 2013-06-13 Singapore Volition Pte Limited Method for detecting nucleosome adducts
EP2820129A1 (en) 2012-03-02 2015-01-07 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
GB201303576D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for predicting therapy efficacy using nucleosome structure biomarkers
EP2971100A1 (en) 2013-03-13 2016-01-20 Sequenom, Inc. Primers for dna methylation analysis
EP3736344A1 (en) 2014-03-13 2020-11-11 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
JP6668255B2 (ja) * 2014-04-30 2020-03-25 エクスプレッション、パソロジー、インコーポレイテッドＥｘｐｒｅｓｓｉｏｎ Ｐａｔｈｏｌｏｇｙ， Ｉｎｃ． アンドロゲン受容体（ａｒ）タンパク質のｓｒｍ／ｍｒｍアッセイ
CN107209190B (zh) 2014-10-29 2021-07-16 比利时意志有限责任公司 用于富集循环肿瘤dna的方法
GB201421933D0 (en) * 2014-12-10 2015-01-21 Singapore Volition Pte Ltd Method for a detection of hormone sensitive diease progression
GB201511512D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell-free nucleosomes as biomarkers
GB201511542D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell free nucleosomes as biomarkers
GB201518665D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for enrichment of cell free nucleosomes
GB201518674D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for detecting nuleosomes containing histone modifications and variants
GB201604806D0 (en) * 2016-03-22 2016-05-04 Singapore Volition Pte Ltd Method of identifying a cancer of unknown origin
GB201612815D0 (en) * 2016-07-25 2016-09-07 Belgian Volition Sa Novel combination test
WO2019053243A1 (en) 2017-09-18 2019-03-21 Santersus Sa METHOD AND DEVICE FOR PURIFYING BLOOD OF FREE CIRCULATING DNA
GB201721569D0 (en) 2017-12-21 2018-02-07 Belgian Volition Sprl Method for the detection and treatment of colorectal adenomas
WO2019175876A2 (en) * 2018-03-13 2019-09-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Diagnostic use of cell free dna chromatin immunoprecipitation
GB201818963D0 (en) 2018-11-21 2019-01-09 Belgian Volition Sprl Methof for the detection of prostate cancer
GB201818965D0 (en) 2018-11-21 2019-01-09 Belgian Volition Sprl Method for the detection of colorectal cancer
GB201906199D0 (en) 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
GB201906201D0 (en) 2019-05-02 2019-06-19 Belgian Voltion Sprl Method for the detection of protate cancer
GB201912251D0 (en) 2019-08-27 2019-10-09 Belgian Volition Sprl Method of isolating circulating nucleosomes
WO2021038010A1 (en) 2019-08-27 2021-03-04 Belgian Volition Sprl Method of isolating circulating nucleosomes
AU2020395504A1 (en) 2019-12-02 2022-06-23 Belgian Volition Srl Use of cell free nucleosomes as biomarkers
AU2021238782A1 (en) 2020-03-20 2022-09-22 Belgian Volition Srl Triaging method using cell free nucleosome levels
CN111413497A (zh) * 2020-04-15 2020-07-14 上海市东方医院（同济大学附属东方医院） 组蛋白甲基转移酶ezh2在制备用于诊断脓毒症的生物标记物中的用途
JP2023544112A (ja) 2020-09-21 2023-10-20 ベルジアン ボリション エスアールエル 血液中の遊離ヌクレオソームのインラインモニタリングのための装置
TW202238131A (zh) 2020-11-25 2022-10-01 比利時商比利時意志有限公司 測量無細胞核蛋白染色質片段之方法
TW202238132A (zh) 2020-12-08 2022-10-01 比利時商比利時意志有限公司 多發性硬化症之診斷方法
TW202242145A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析
TW202242130A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 循環轉錄因子分析
TW202242146A (zh) 2021-01-13 2022-11-01 比利時商比利時意志有限公司 肺癌的檢測方法
GB202108185D0 (en) 2021-06-08 2021-07-21 Belgian Volition Sprl Standardisation of nucleosome assays using biologically derived calibrants
GB202108452D0 (en) 2021-06-14 2021-07-28 Belgian Volition Sprl Triaging method using cell free nucleosome levels
WO2023073179A1 (en) 2021-10-29 2023-05-04 Belgian Volition Srl Homogeneous immunoassay method
GB202117799D0 (en) 2021-12-09 2022-01-26 Belgian Volition Srl Method for the detection of blood cancer
WO2023170298A1 (en) 2022-03-11 2023-09-14 Belgian Volition Srl Differential diagnosis method
GB202205212D0 (en) 2022-04-08 2022-05-25 Belgian Volition Sprl Method for transplant organ health assessment
WO2024042210A1 (en) 2022-08-25 2024-02-29 Belgian Volition Srl Method for measuring cell free chromatin
WO2024042208A1 (en) 2022-08-25 2024-02-29 Belgian Volition Srl Method for the detection of dementia

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2652901A1 (fr) 1989-10-11 1991-04-12 Pasteur Institut Complexes biologiques a base de nucleosomes, et leurs applications, notamment dans le domaine du diagnostic in vitro du lupus erythemateux dissemine (led).
ATE329264T1 (de) * 1998-03-18 2006-06-15 Roche Diagnostics Gmbh Nachweis von produkten von apoptosis
JP2001029077A (ja) * 1999-07-21 2001-02-06 Yoshihiro Koseki 新規ｍｉｔｅ様因子
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
GB0319376D0 (en) * 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
WO2005040814A1 (en) 2003-10-14 2005-05-06 Cancer Research Technology Limited Methods and means of cancer detection by histone modification
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
RU2322264C1 (ru) * 2006-07-27 2008-04-20 Михаил Аркадьевич Шурдов Способ лечения заболеваний
RU2640247C2 (ru) * 2007-04-05 2017-12-27 Зюмбиотек Гезелльшафт Цур Форшунг Унд Энтвиклунг Ауф Дем Гебит Дер Биотехнологи Мбх БИС-Met-ГИСТОНЫ
PL2865387T3 (pl) 2008-11-21 2019-12-31 Københavns Universitet (University Of Copenhagen) Pobudzenie odpowiedzi odpornościowej
BRPI1013546A2 (pt) * 2009-04-14 2019-04-09 The Regente Of The University Of California usos de um inibidor da timidilato sintase e de uma terapia anticâncer
WO2011131772A1 (en) 2010-04-22 2011-10-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
FI20105715A0 (fi) 2010-06-18 2010-06-18 Helsingin Yliopisto Asetyloituun HMGB1:een sitoutuva polyklonaalinen vasta-aine
CN102147409B (zh) * 2010-12-31 2016-06-22 深圳市亚辉龙生物科技股份有限公司 一种测定抗核小体抗体IgG的方法及试剂装置
EP2684604A4 (en) 2011-03-08 2014-12-31 Mitsubishi Plastics Inc CATALYST, ELEMENT FOR REMOVING STAIN OXIDE AND SYSTEM FOR REMOVING STAIN OXIDE
WO2013084002A2 (en) 2011-12-07 2013-06-13 Singapore Volition Pte Limited Method for detecting nucleosome adducts

Also Published As

Publication number Publication date
EP3264090A2 (en) 2018-01-03
US9187780B2 (en) 2015-11-17
US20160097772A1 (en) 2016-04-07
PL2788767T3 (pl) 2018-03-30
HUE035855T2 (en) 2018-05-28
US20140322719A1 (en) 2014-10-30
US20170276684A1 (en) 2017-09-28
JP2015500478A (ja) 2015-01-05
EP3264090A3 (en) 2018-03-28
SG11201402982TA (en) 2014-07-30
HK1249176A1 (zh) 2018-10-26
RU2014127493A (ru) 2016-01-27
US11193939B2 (en) 2021-12-07
AU2012349855B2 (en) 2017-12-07
EP2788767A2 (en) 2014-10-15
AU2012349855A1 (en) 2014-05-22
EP2788767B1 (en) 2017-09-06
EP3264090B1 (en) 2022-05-18
MX356986B (es) 2018-06-22
EP4092415A1 (en) 2022-11-23
ZA201403260B (en) 2015-07-29
ES2649404T3 (es) 2018-01-11
CN104067125A (zh) 2014-09-24
CN104067125B (zh) 2017-12-26
JP6263474B2 (ja) 2018-01-17
WO2013084002A2 (en) 2013-06-13
KR20140109871A (ko) 2014-09-16
KR102039756B1 (ko) 2019-11-01
DK2788767T3 (da) 2017-11-27
MX2014006866A (es) 2014-11-10
HK1202926A1 (en) 2015-10-09
BR112014013082B1 (pt) 2021-02-02
PT2788767T (pt) 2017-12-06
HRP20171680T1 (hr) 2018-04-06
SG10201604081YA (en) 2016-07-28
CA2855375C (en) 2021-06-22
US9709569B2 (en) 2017-07-18
RU2634266C2 (ru) 2017-10-24
CA2855375A1 (en) 2013-06-13
WO2013084002A3 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
BR112014013082A2 (pt) método para detectar adutos nucleossomos
EA201590027A1 (ru) Способы детекции заболеваний или состояний
MX349561B (es) Método para detectar nucleosomas que contienen variantes de histonas.
TR201904386T4 (tr) Nükleotidleri içeren nükleozomların saptanmasına yönelik yöntem.
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
ATE554389T1 (de) Apex als marker für lungenkrebs
GB201305223D0 (en) Reflection detection type measurement apparatus for skin autofluorescence
BR112013010952A2 (pt) sistemas de rmn e métodos para a detecção rápida de analisados
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
EA201370063A1 (ru) Фосфолипидом рака
WO2014020502A3 (en) Markers associated with sensitivity to inhibitors of human double minute 2 (mdm2)
CA2839777C (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
BR112016001957A2 (pt) biossensor
CY1122360T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
BR112016007037A2 (pt) método para detectar câncer pancreático, anticorpo monoclonal e kit
BR112014031958A2 (pt) bag3 como marcador de tecido e soro bioquímico
BR112016002668A2 (pt) métodos e kits para prognosticar o risco de ter uma doença ou evento cardiovasculares
CY1123265T1 (el) Μια αναλυση κυτταρικως μεσολαβουμενης ανοσοαποκρισhς
BR112014007556A2 (pt) método de determinação de sinais estacionários para o diagnóstico de um sistema eletromecânico
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
WO2013167727A3 (en) Method for determining arthritis relapse risk
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/12/2012, OBSERVADAS AS CONDICOES LEGAIS.